Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI

Description

The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.

Conditions

Glioblastoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.

Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI

Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI

Condition
Glioblastoma
Intervention / Treatment

-

Contacts and Locations

Milwaukee

Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV.
  • * Optune compliance \< 75%; they would be excluded from the final analyses.
  • * History of craniectomy or significant skull defect (contraindication to Optune).
  • * Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).
  • * Karnofsky Performance Status (KPS) \< 60.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medical College of Wisconsin,

Jennifer Connelly, MD, PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

2023-12-31